Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Acute myeloid leukemia (AML) is not hereditary, but a person may inherit gene mutations that make the condition more likely. Having a close family member with AML can also increase the risk. Acute ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results